Hong Kong
· Delayed Price · Currency is HKD Clover Biopharmaceuticals Company Description
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China.
Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis.
The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment.
In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 387 |
| CEO | Joshua G. Liang |
Contact Details
Address: No. 758 West Nanjing Road Shanghai China | |
| Website | cloverbiopharma.com |
Stock Details
| Ticker Symbol | 2197 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG2280A1076 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joshua G. Liang | Chief Executive Officer and Executive Director |
| Dr. Peng Liang Ph.D. | Founder, Chief Scientific Officer and Chairman of the Board |
| Dr. Yang Li Ph.D. | Chief Technology Officer |
| Htay Htay Han MBBS | Chief Medical Officer of Vaccine |
| Dr. Berry Michael Ph.D. | Chief Technical Operation Officer |